Kallikrein 4 is a potential mediator of cellular interactions between cancer cells and osteoblasts in metastatic prostate cancer
- PMID: 17221837
- DOI: 10.1002/pros.20465
Kallikrein 4 is a potential mediator of cellular interactions between cancer cells and osteoblasts in metastatic prostate cancer
Abstract
Background: Prostate cancer (PCa) and bone cell interactions are critical in the metastatic phase. Kallikrein 4 (KLK4/hK4) is expressed in both PCa and mineralized tissues. We determined if KLK4/hK4 expression was associated with, and influenced by, the bone environment of metastatic PCa.
Methods: Immunohistochemistry, in vitro co-culture, cell migration, and attachment assays.
Results: hK4 was localized to tumor cells and osteoblasts in bone metastases. KLK4/hK4 increased in LNCaP and PC3 cells co-cultured with SaOs2 cells; SaOs2 KLK4/hK4 was unchanged. Co-culture did not affect cell proliferation but altered alkaline phosphatase activity/mRNA levels in SaOs2 cells. KLK4-transfected PC3 cells had increased migration towards SaOs2 conditioned medium and greater attachment to the bone-matrix proteins, collagens I and IV.
Conclusions: hK4 expression and interaction with both tumor cells and osteoblasts suggests a role for hK4 in PCa bone metastasis. Whether this observation is unique to bone metastasis or reflects a role for hK4 in PCa metastasis generally is yet to be established.
Similar articles
-
Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells.Endocr Relat Cancer. 2005 Sep;12(3):631-43. doi: 10.1677/erc.1.00958. Endocr Relat Cancer. 2005. PMID: 16172196
-
Compartmentalized expression of kallikrein 4 (KLK4/hK4) isoforms in prostate cancer: nuclear, cytoplasmic and secreted forms.Endocr Relat Cancer. 2005 Dec;12(4):875-89. doi: 10.1677/erc.1.01062. Endocr Relat Cancer. 2005. PMID: 16322328
-
Prostate-specific kallikreins-2 and -4 enhance the proliferation of DU-145 prostate cancer cells through protease-activated receptors-1 and -2.Mol Cancer Res. 2008 Jun;6(6):1043-51. doi: 10.1158/1541-7786.MCR-08-0096. Mol Cancer Res. 2008. PMID: 18567807
-
The role of tumor microenvironment in prostate cancer bone metastasis.J Cell Biochem. 2007 Jul 1;101(4):873-86. doi: 10.1002/jcb.21214. J Cell Biochem. 2007. PMID: 17387734 Review.
-
Epithelial-mesenchymal transition in prostate cancer and the potential role of kallikrein serine proteases.Cells Tissues Organs. 2007;185(1-3):111-5. doi: 10.1159/000101311. Cells Tissues Organs. 2007. PMID: 17587816 Review.
Cited by
-
Kallikrein-Related Peptidases in Prostate Cancer: From Molecular Function to Clinical Application.EJIFCC. 2014 Oct 24;25(3):269-81. eCollection 2014 Oct. EJIFCC. 2014. PMID: 27683474 Free PMC article.
-
A variant of the KLK4 gene is expressed as a cis sense-antisense chimeric transcript in prostate cancer cells.RNA. 2010 Jun;16(6):1156-66. doi: 10.1261/rna.2019810. Epub 2010 Apr 20. RNA. 2010. PMID: 20406994 Free PMC article.
-
Functional roles of human kallikrein-related peptidases.J Biol Chem. 2009 Nov 27;284(48):32989-94. doi: 10.1074/jbc.R109.027946. Epub 2009 Oct 9. J Biol Chem. 2009. PMID: 19819870 Free PMC article. Review.
-
KLK4 Induces Anti-Tumor Effects in Human Xenograft Mouse Models of Orthotopic and Metastatic Prostate Cancer.Cancers (Basel). 2020 Nov 24;12(12):3501. doi: 10.3390/cancers12123501. Cancers (Basel). 2020. PMID: 33255452 Free PMC article.
-
Clinical significance of kallikrein-related peptidase-4 in oral cancer.Anticancer Res. 2015 Apr;35(4):1861-6. Anticancer Res. 2015. PMID: 25862839 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical